Article
The FDA has consolidated three existing areas within the Center for Drug Evaluation and Research to form the Office of Oncology Drug Products.
Phase 2 trial launches of opaganib plus darolutamide in mCRPC
Identifying Patients with Intermediate Risk in NMIBC
Study points to increasing incidence of advanced prostate cancer in California
Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
Hundreds of future urologists celebrate Urology Match Day 2025
Acute toxicity after prostate cancer radiotherapy increases odds of late toxicity